2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2987

RAPID Remission during the First Year in EARLY ACTIVE Rheumatoid Arthritis Is Associated with Better 5 YEARS Structural Damage Outcomes
Abstract Number: 2988

Characteristics and Outcomes in a Prospective Cohort of Patients with Aortitis Diagnosed Following Surgical Resection
Abstract Number: 2989

Cardiac Involvement in Systemic Vasculitis: A Retrospective Pathological Study
Abstract Number: 2990

Do Polymyalgia Rheumatica Patients Have an Increased Risk of Cardiovascular Events?: A Matched-Control Study
Abstract Number: 2991

Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study
Abstract Number: 2992

Are Specific Vascular Symptoms in Takayasu’s Arteritis Reflective of Vascular Inflammation, Vascular Damage, or Both?
Abstract Number: 2993

Vascular Involvement in Behcet’s Syndrome May be Associated with Subclinical Atherosclerosis
Abstract Number: 2994

Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK
Abstract Number: 2995

Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Abstract Number: 2996

The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Medicaid Cohort Stratified By Disease Severity
Abstract Number: 2997

Association between Payments By Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology
Abstract Number: 2998

Opioid Use Among SLE Patients and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Abstract Number: 2999

Does the Incremental Cost of ACPA-Positive Rheumatoid Arthritis Patients Vary By the Care Pathway They Follow?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].